Search clinical trials for: MK-3475

Total 2281 results

Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Treating Participants With Leukoplakia

Leukoplakia | Erythroleukoplakia | Verrucous Oral Leukoplakia

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Washington University School of Medicine
Eli Lilly and Company

Recruiting

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

Recurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2

United States
Roswell Park Cancer Institute

Active, not recruiting

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Joel Neal
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Locally Advanced Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Stage III Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Urinary Bladder, Overactive
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
GWT-TUD GmbH
PharmaMar

Completed

Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma (YonLife)

Soft Tissue Sarcoma

Germany
NYU Langone Health

Recruiting

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung)

NSCLC Stage IV

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Stage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
Oncorus, Inc.
Merck Sharp & Dohme LLC

Terminated

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Melanoma | Cancer | Breast Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Liver Metastases | Colorectal Carcinoma | Non-melanoma Skin Cancer

United States, Canada
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Relapsed Classical Hodgkin Lymphoma

United States
Sellas Life Sciences Group
Merck Sharp & Dohme LLC; Cancer Insight, LLC

Active, not recruiting

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Colorectal Cancer | Ovarian Cancer | Acute Myelogenous Leukemia | Small-cell Lung Cancer | Triple-negative Breast Cancer

United States
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
University of Washington
Merck Sharp & Dohme LLC

Withdrawn

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Relapsed Acute Myeloid Leukemia

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Terminated

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
Merck Sharp & Dohme LLC

Terminated

A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)

Osteoporosis
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC

Recruiting

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)

Small Cell Ovarian Carcinoma

France
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
Bennett, Robert, M.D.
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Fibromyalgia

United States
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
University of Colorado, Denver
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

Neoplasm Metastasis

United States, Canada, France, Germany, Hungary, Israel, Italy, Japan, Norway, Peru, Poland, Portugal, Spain, Taiwan
Anuradha Krishnamurthy
Merck Sharp & Dohme LLC

Completed

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Immutep S.A.S.
Merck Sharp & Dohme LLC

Active, not recruiting

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)

NSCLC | HNSCC

Spain, United States, United Kingdom, Australia, Ukraine
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides... and other conditions

United States
Julie Graff, MD
Johns Hopkins University; Merck Sharp & Dohme LLC; Oregon Health and Science... and other collaborators

Recruiting

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Prostate Cancer | Prostate Cancer Metastatic

United States
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Jonathan Trent, MD, PhD
Merck Sharp & Dohme LLC; Pfizer

Completed

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

Alveolar Soft Part Sarcoma | Soft Tissue Sarcomas

United States
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Chile, Australia, Israel, New Zealand
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Type 2 Diabetes Mellitus
Immutep S.A.S.
Merck Sharp & Dohme LLC

Recruiting

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)

HNSCC

United States, Belgium, Spain, United Kingdom, Denmark, Germany, Australia, Romania, Ukraine
Sidney Kimmel Cancer Center at Thomas Jefferson...
Merck Sharp & Dohme LLC

Completed

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Head and Neck Squamous Cell Carcinoma | Metastatic Renal Cell Cancer | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Lung Cancer | Stage IV Skin Melanoma

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Poland, Canada, Lithuania, Norway, Italy
George Albert Fisher
Merck Sharp & Dohme LLC

Completed

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Gastric Adenocarcinoma | Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Unresectable Esophageal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma

United States

Search clinical trials for: MK-3475

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations